Editas Medicine (EDIT) financial statements
Editas Medicine reported revenue of $41M in fiscal 2025, up 23.5% a year over 9 years.
Net income was -$160M and the operating margin -394.9%, against -1605.6% in 2016.
Free cash flow was -$166M.
The diluted share count rose 175% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Editas Medicine's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $14M | $32M | $21M | $91M | $26M | $20M | $78M | $32M | $41M |
| Research and development | $57M | $83M | $91M | $97M | $158M | $143M | $175M | $178M | $199M | $90M |
| Selling, general and admin | $46M | $51M | $55M | $65M | $68M | $76M | $71M | $70M | $72M | $50M |
| Operating income | -$97M | -$120M | -$114M | -$141M | -$135M | -$193M | -$226M | -$169M | -$251M | -$160M |
| Interest expense | — | — | — | — | — | — | — | — | $2M | $6M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$97M | -$120M | -$110M | -$134M | -$116M | -$193M | -$220M | -$153M | -$237M | -$160M |
| EPS (diluted) | -$3.02 | -$2.98 | -$2.33 | -$2.68 | -$1.98 | -$2.85 | -$3.21 | -$2.02 | -$2.88 | -$1.80 |
| Diluted shares | 32M | 40M | 47M | 50M | 59M | 68M | 69M | 76M | 82M | 89M |
| Operating margin | -1605.6% | -873.6% | -356.1% | -686.4% | -148.6% | -756.1% | -1146.3% | -216.6% | -777.2% | -394.9% |
| Net margin | -1605.5% | -876.5% | -344.3% | -651.4% | -127.8% | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
Balance sheet
Fiscal years, from Editas Medicine's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $185M | $329M | $369M | $457M | $402M | $500M | $344M | $323M | $270M | $147M |
| Receivables | $88,000 | $679,000 | $30,000 | $418,000 | $6M | $267,000 | $5M | $10M | $16M | $15M |
| Total current assets | $187M | $332M | $375M | $464M | $419M | $507M | $357M | $341M | $289M | $164M |
| Property, plant and equipment | $40M | $39M | $40M | $11M | $14M | $17M | $16M | $12M | $14M | $4M |
| Total assets | $229M | $373M | $420M | $509M | $573M | $677M | $514M | $499M | $342M | $187M |
| Total current liabilities | $33M | $37M | $36M | $60M | $58M | $47M | $60M | $63M | $77M | $46M |
| Long-term debt | — | — | — | — | — | — | — | $0 | $52M | $54M |
| Total liabilities | $95M | $165M | $184M | $246M | $179M | $124M | $154M | $150M | $207M | $159M |
| Shareholders' equity | $135M | $208M | $236M | $262M | $394M | $554M | $361M | $349M | $134M | $27M |
| Net debt | -$185M | -$147M | -$135M | -$238M | -$140M | -$204M | -$142M | -$124M | -$74M | -$88M |
Cash flow
Fiscal years, from Editas Medicine's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$50M | -$9M | -$46M | -$41M | -$180M | -$164M | -$177M | -$132M | -$210M | -$165M |
| Capital spending | $3M | $2M | $5M | $6M | $7M | $8M | $4M | $5M | $9M | $607,000 |
| Free cash flow | -$54M | -$11M | -$50M | -$47M | -$187M | -$172M | -$181M | -$137M | -$219M | -$166M |
| Stock-based compensation | $17M | $23M | $27M | $27M | $23M | $43M | $29M | $20M | $21M | $10M |
| Net borrowing | — | — | — | — | — | — | — | — | $57M | -$3M |
| Free cash flow margin | -887.8% | -83.6% | -158.0% | -228.1% | -206.1% | -672.5% | -920.6% | -175.2% | -678.1% | -409.3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EDIT.
Open EDIT in InvestinglyQuestions
What was Editas Medicine's revenue in 2025?
$41M in fiscal 2025, from its 10-K filing.
How much free cash flow does Editas Medicine generate?
-$166M in fiscal 2025 (operating cash flow minus capital spending).
From Editas Medicine's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.